SutroVax heading to clinic with potential competitor to Pfizer’s Prevnar 13

With its new $110 million series D round, SutroVax is preparing for its first clinical trial that could test its 24-valent pneumonia vaccine against Prevnar 13 -- or a next-generation version.

RA Capital and Janus Henderson investors led SutroVax Inc.’s round. Also participating were all of the company’s existing institutional investors TPG Growth, Abingworth, Longitude Capital, Frazier Healthcare Partners, Pivotal bioVenture Partners, Medicxi, CTI Life Sciences, Roche Venture Fund and Foresite Capital...